Manuel Modiano Revah, MD
Hematology & Oncology · Tucson, AZNPI 1003864380
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Karyopharm Therapeutics Inc. at 49.4% of the total. Reporting peaked in 2021 at $1,512 and has fallen 76.9% since, to $349 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AZ, where the typical reported total is $6,870.
Across 75 payments — averaging $40.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Karyopharm Therapeutics Inc.$2K
- Johnson & Johnson$185
- Merck$131
- Incyte Corporation$123
- Bristol Myers Squibb$104
- E.r. Squibb & Sons, L.L.C.$88
- plus $904 from 26 others
Across 806 payments — averaging $2061.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$488K
- Genentech, Inc.$424K
- Regeneron$271K
- AstraZeneca$157K
- Spectrum Pharmaceuticals Inc.$84K
- E.r. Squibb & Sons, L.L.C.$73K
- plus $165K from 10 others
What the payments were for
- Consulting fees$1,50049%
- Food & beverage$1,26642%
- Education$2689%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Karyopharm Therapeutics Inc. | 1 | $1,500 |
| Johnson & Johnson(2 entities) | 5 | $185 |
| Merck | 10 | $131 |
| Incyte Corporation | 3 | $123 |
| Bristol Myers Squibb | 4 | $104 |
| E.r. Squibb & Sons, L.L.C. | 6 | $88 |
| Pfizer | 5 | $87 |
| Novartis | 4 | $75 |
| GSK | 1 | $67 |
| Genentech USA, Inc. | 3 | $57 |
| Sanofi | 2 | $53 |
| AVEO Pharmaceuticals, Inc. | 2 | $52 |
| AstraZeneca | 3 | $48 |
| Lilly USA, LLC | 3 | $41 |
| Bayer | 2 | $39 |
| Array Biopharma Inc | 2 | $35 |
| Astellas Pharma US Inc | 2 | $32 |
| Abbott | 1 | $29 |
| Fresenius Kabi USA, LLC | 1 | $26 |
| Gilead | 2 | $26 |
| Stemline Therapeutics Inc. | 1 | $24 |
| AbbVie | 1 | $23 |
| EMD Serono, Inc. | 2 | $22 |
| Genentech, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| CTI Biopharma Corp. | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
| Exelixis Inc. | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Springworks Therapeutics, Inc. | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
| Taiho Oncology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPOVIO$1,500
How this compares
$3,034 in reported general payments places this provider in the 35th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 30 | $626,478 |
| PomalystPomalidomide | 11 | $257,371 |
| Lenalidomide | 14 | $229,929 |
| IbrancePalbociclib | 12 | $222,093 |
| ImbruvicaIbrutinib | 13 | $213,145 |
| XtandiEnzalutamide | 11 | $157,768 |
| TasignaNilotinib Hcl | 13 | $139,432 |
| EliquisApixaban | 34 | $34,966 |
| XareltoRivaroxaban | 22 | $29,712 |
| Hydroxyurea | 33 | $1,665 |
| Anastrozole | 125 | $1,569 |
| ValacyclovirValacyclovir Hcl | 20 | $1,474 |
| Exemestane | 11 | $1,429 |
| Ondansetron OdtOndansetron | 11 | $597 |
| Gabapentin | 20 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $104 | $626,47830 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $88 | $257,37111 claims |
| PfizerIbrance, Eliquis | $87 | $257,05946 claims |
| Astellas Pharma US IncXtandi | $32 | $157,76811 claims |
| NovartisTasigna | $75 | $139,43213 claims |
| Johnson & JohnsonXarelto | $185 | $29,71222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Tucson
- Christopher ChenTucson$370K
- Rachna ShroffTucson$250K
- Alison StopeckTucson$115K
- Jaspreet ChahalTucson$104K
- Basel ShouaTucson$98K
- Akshay AmaraneniTucson$93K
- Ahmed AbdelazizTucson$35K
- Michael BoxerTucson$30K
- Catherine AzarTucson$29K
- Ricklie JulianTucson$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.